GlassScriptPhysician profile
Timothy Mecredy
NPI 1831233063
$8,468.16
in general payments reported to CMS, 2019-2025
36 companies · $1,886 in 2025
The $1,886 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $655 · 2020: $707 · 2021: $1,381 · 2022: $1,640 · 2023: $882 · 2024: $1,317 · 2025: $1,886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,065 · Education: $19.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,065.34 |
| Education | $19.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,384.48 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,054.07 | 2019-2025 | Xifaxan, Trulance |
| Fujifilm Healthcare Americas Corporation | $631.11 | 2020-2021 | |
| Janssen Biotech, INC. | $625.12 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $357.60 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $343.60 | 2019-2025 | Entyvio, Gattex |
| Genzyme Corporation | $343.15 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $305.68 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $264.97 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $218.47 | 2020-2025 | Sucraid, Sucraid |
| Janssen Scientific Affairs, LLC | $181.51 | 2021-2022 | |
| Gilead Sciences, INC. | $181.46 | 2021-2025 | |
| Boston Scientific Corporation | $178.97 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $144.64 | 2021-2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $129.06 | 2022-2025 | Dupixent |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $125.01 | 2022 | |
| Ironwood Pharmaceuticals, INC | $114.25 | 2019-2024 | |
| Celgene Corporation | $104.00 | 2022-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $86.84 | 2020-2023 | Rebyota |
| Ipsen Biopharmaceuticals, INC | $83.56 | 2025 | Iqirvo |
| Medtronic, INC. | $69.00 | 2021 | |
| Merck Sharp & Dohme LLC | $68.08 | 2022-2024 | Dificid |
| Ucb, INC. | $61.85 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $61.56 | 2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $57.60 | 2021-2023 | |
| Braintree Laboratories, INC. | $45.08 | 2019-2023 | Sutab |
| Lilly USA, LLC | $42.39 | 2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $39.47 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $27.34 | 2025 | Terlivaz |
| Redhill Biopharma INC. | $24.93 | 2020 | |
| Dova Pharmaceuticals | $24.28 | 2019 | |
| Biocon Biologics INC | $21.09 | 2025 | Yesintek |
| Shield Therapeutics INC | $19.58 | 2025 | |
| Celltrion USA INC. | $19.44 | 2024 | Zymfentra |
| Ardelyx, INC. | $17.17 | 2024 | Ibsrela |
| Allergan, INC. | $11.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Mecredy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.